ARTICLE | Clinical News
Omacetaxine mepesuccinate regulatory update
June 4, 2012 7:00 AM UTC
Teva said FDA accepted for review an NDA for omacetaxine to treat chronic myelogenous leukemia (CML) in patients who have resistance and/or intolerance to two or more tyrosine kinase inhibitors, inclu...